Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (101-110 of 312) with videos related to

Pageof 32
Sort By:
Prostate Cancer and Prostatic Diseases|March 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT studyNeal D Shore, Daniel J George, Nasreen Khan, et al.
Reviews in Urology|October 23, 2014
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate CancerVladimir Mouraviev, Neil Mariados, David Albala, et al.
Future Oncology (London, England)|November 6, 2024
Plain language review: the safety of relugolix combination therapy for advanced prostate cancerJose De La Cerda, Jared Thorley, Paul Sieber, et al.
Clinical Therapeutics|May 4, 2010
Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter studyMichael Marberger, Amir V Kaisary, Neal D Shore, et al.
Cancer|May 26, 2017
Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized diseaseTracy T Li, Neal D Shore, Maneesha Mehra, et al.
Future Oncology (London, England)|July 10, 2025
Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary reviewTaeweon Lee, Ayushi Gianchandani, Stephen A Boorjian, et al.
Clinical Genitourinary Cancer|September 2, 2019
Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)Neal D Shore, Daniel Saltzstein, Paul Sieber, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Clinical Genitourinary Cancer|December 3, 2017
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate CancerNeal D Shore, Ronald F Tutrone, Neil F Mariados, et al.
Targeted Oncology|December 6, 2022
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for MetastasesGordon Brown, Laurence Belkoff, Jason M Hafron, et al.
Pageof 32

Showing results (101-110 of 312) with videos related to

Sort By:
Pageof 32
Prostate Cancer and Prostatic Diseases|March 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT studyNeal D Shore, Daniel J George, Nasreen Khan, et al.
Reviews in Urology|October 23, 2014
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate CancerVladimir Mouraviev, Neil Mariados, David Albala, et al.
Future Oncology (London, England)|November 6, 2024
Plain language review: the safety of relugolix combination therapy for advanced prostate cancerJose De La Cerda, Jared Thorley, Paul Sieber, et al.
Clinical Therapeutics|May 4, 2010
Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter studyMichael Marberger, Amir V Kaisary, Neal D Shore, et al.
Cancer|May 26, 2017
Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized diseaseTracy T Li, Neal D Shore, Maneesha Mehra, et al.
Future Oncology (London, England)|July 10, 2025
Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary reviewTaeweon Lee, Ayushi Gianchandani, Stephen A Boorjian, et al.
Clinical Genitourinary Cancer|September 2, 2019
Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)Neal D Shore, Daniel Saltzstein, Paul Sieber, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Clinical Genitourinary Cancer|December 3, 2017
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate CancerNeal D Shore, Ronald F Tutrone, Neil F Mariados, et al.
Targeted Oncology|December 6, 2022
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for MetastasesGordon Brown, Laurence Belkoff, Jason M Hafron, et al.
Pageof 32